Jaguar Animal Health, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.
Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding. The company is headquartered in East Windsor, New Jersey, and maintains a streamlined development organization designed to advance lead candidates from proof-of-concept through regulatory approvals and commercial launch.
Among Jaguar’s key offerings is a proprietary probiotic formulation intended to reduce the incidence and severity of post-weaning diarrhea in piglets, which has received regulatory clearance in select markets. In parallel, the company is progressing a complementary feed-additive candidate for controlling necrotic enteritis in broiler chickens. Jaguar leverages in-house expertise in microbial therapeutics to optimize dosing regimens and demonstrate consistent performance under commercial farming conditions.
To date, Jaguar Animal Health serves customers primarily in Latin America through strategic distribution partnerships, while preparing for broader market entry in North America. The company’s leadership team brings experience in veterinary development, regulatory affairs, and commercial operations, positioning Jaguar to address growing global demand for effective, antibiotic-reducing solutions in livestock production.
AI Generated. May Contain Errors.
